Phase II trial of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin (MOF-Strep) in patients with disseminated pancreatic carcinoma.
A phase II trial of methyl-CCNU, 5-fluorouracil (5-Fu), vincristine, and streptozotocin (MOF-Strep) was conducted on 20 patients with pancreatic carcinoma. There were two partial remissions (10%) lasting 3 and 10 months. In addition, there were two minor responses. The predominant toxicity was gastrointestinal, although hematologic and renal toxicity were also seen. Since the response rate to MOF-Strep does not appear to exceed that to 5-Fu alone, the usefulness of this combination in patients with pancreatic carcinoma is limited.
D000230:Adenocarcinoma / Q000188:drug therapy*; D007516:Adenoma, Islet Cell / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D012673:Semustine / Q000627:therapeutic use*; D013311:Streptozocin / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use*
D009607:Nitrosourea Compounds; D012673:Semustine; D014750:Vincristine; D013311:Streptozocin; D005472:Fluorouracil